Replies to post #448875 on Anavex Life Sciences Corp (AVXL)

[bas2020]

More outrageous nonsense from a known paid FUDster! 👺

These FACTS aren't mine, they're Anavex's trial results...

• Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% CI) 1.839 (1.17, 2.94) P = 0.015

• Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% CI) 2.67 (1.17, 6.13) P = 0.0255

• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• Mean difference in ADAS-Cog score change of -1.85 points

• Compared to placebo, ANAVEX®2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by CDR-SB

• ADCS-Cog and CDR-SB (p < .025) proving further significance of stat. sig. improvements and trial success.

• Identification of two key biomarkers (Aß42/40 ratio and brain volume stabilization) for AA pathway option.

As stated by the company...
After reviewing all of the data (published and unpublished), the EMA recommended that Anavex apply for FULL APPROVAL.